You are here

  • Home
  • Archive
  • Volume 73, Issue 6
  • Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, …

Article metrics

Article menu
Clinical and epidemiological research
Extended report
Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial

 

Online download statistics by month:

Online download statistics by month: January 2014 to September 2024

AbstractFullPdf
Jan 201433511145
Feb 2014727657736
Mar 2014257440394
Apr 2014319335475
May 20142151608552
Jun 2014833310267
Jul 2014382330179
Aug 2014275289172
Sep 2014229308158
Oct 2014173276144
Nov 2014149232132
Dec 2014154241113
Jan 201515824993
Feb 2015132220104
Mar 2015181255124
Apr 2015133198105
May 201514818990
Jun 201514624689
Jul 2015136207109
Aug 2015147212101
Sep 2015142216108
Oct 20159014891
Nov 201510317570
Dec 201511417491
Jan 201613819387
Feb 2016122190108
Mar 2016156185119
Apr 2016166172129
May 2016121173120
Jun 2016125298111
Jul 201611311886
Aug 2016114172112
Sep 201613115981
Oct 2016134205109
Nov 201610714380
Dec 20169013060
Jan 20178219683
Feb 20174920178
Mar 201739185141
Apr 201750237104
May 20174021291
Jun 20178418991
Jul 2017264226159
Aug 2017310228153
Sep 2017264217163
Oct 2017352285181
Nov 2017314209147
Dec 2017266162115
Jan 2018262188153
Feb 2018300194116
Mar 201826920198
Apr 201826019496
May 2018265220106
Jun 201828722272
Jul 201821615090
Aug 2018473131201
Sep 201824214478
Oct 201823314375
Nov 201825818592
Dec 201821615247
Jan 201920317869
Feb 201915112944
Mar 201917613374
Apr 201915711285
May 201915811283
Jun 201913710262
Jul 2019164125105
Aug 201917714084
Sep 201915813063
Oct 201917912848
Nov 201917513182
Dec 201917915179
Jan 202016212070
Feb 202013510664
Mar 202014610162
Apr 202018012882
May 2020155127119
Jun 202012210087
Jul 20201169066
Aug 20201148452
Sep 202013611858
Oct 202016714859
Nov 202013710853
Dec 202015814186
Jan 202119015984
Feb 202114111665
Mar 202114312298
Apr 202115511270
May 202115313972
Jun 202110410454
Jul 202111511565
Aug 202111711456
Sep 202117217256
Oct 202122120279
Nov 202123021882
Dec 202117215560
Jan 202219016170
Feb 202217415552
Mar 2022271257107
Apr 202221119298
May 2022220205105
Jun 202216414653
Jul 202221618861
Aug 202218416843
Sep 202218617165
Oct 202217315157
Nov 202219415382
Dec 202214910724
Jan 202317514561
Feb 202316314932
Mar 202321318951
Apr 202317413563
May 202316314185
Jun 202322017342
Jul 202325020161
Aug 202313111242
Sep 202321318460
Oct 202322919263
Nov 202320818231
Dec 202325623144
Jan 202425319145
Feb 202418916443
Mar 202428124382
Apr 202423520264
May 202444941885
Jun 202416214248
Jul 202426324453
Aug 2024190186127
Sep 202420618255
Total271362406513205